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Background: Major life-threatening complications secondary to cisplatin-based chemotherapy are rare in patients
with testicular germ cell tumour (GCT). The incidence of complications increases with dosage of chemotherapy and
with a variety of patient-related as well as disease-related conditions. We here report the first case of GCT experiencing
as many as four major complications most of which can be explained by the conjunction of several predispositions.
Case presentation: A 48 year old patient with testicular seminoma and bulky retroperitoneal and mediastinal metastases
underwent cisplatin based chemotherapy. During the third cycle of chemotherapy, he developed thrombosis of
the central venous port device, subtotal splenic infarction, and Bleomycin induced pneumonitis (BIP). Three
months after completion of therapy, he was struck by thalamic infarction. Genetic testing then revealed heterozygote
mutation of Factor V Leiden (FVL). He received full-dose warfarin anticoagulation treatment and steroid treatment for
BIP. 18 months thereafter, the patient is still disease-free, oncologically. Neurological symptoms have disappeared, but
pulmonary dysfunction persists with a vital capacity of 50%.
Conclusion: The unique co-incidence of four major complications occurring in this patient were obviously triggered by
the genetically determined predisposition of the patient to thrombotic events (FVL). Additionally, several patient-related
and disease-related conditions contributed to the unique pattern of complications, i.e. (1) the slightly advanced age
(48 years), (2) the prothrombotic condition caused by the disease of cancer, (3) the central venous port device,
(4) retroperitoneal bulky metastasis, and (5) cisplatin chemotherapy. Whether or not FVL contributed to the pulmonary
fibrosis as well, remains elusive. Practically, in the case of one major vascular complication during cisplatin chemotherapy
at standard dose, genetic testing for hereditary thrombophilia should be considered. Thus, precautions for preventing
further complications could be initiated.
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Figure 1 Abdominal computed tomography, coronary section
view showing the large retroperitoneal metastasis of seminoma
before initiation of chemotherapy.
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Testicular germ cell tumours (GCTs) represent a para-
digm for a curable neoplasm [1]. Combination chemo-
therapy with cisplatin, etoposide and bleomycin (PEB)
can cure metastasized disease and even far advanced
disease (i.e. poor prognosis according to the IGCCCG
classification) can be salvaged in about 50% [2]. How-
ever, systemic treatment is quite toxic even by applica-
tion of standard doses and it involves the potential of
numerous adverse reactions arising acutely at the time
of treatment and other sequels developing in the long
term [3]. The most frequent untoward reactions occur-
ring at the time of treatment or immediately thereafter
encompass myelodepression with neutropenic fever, alo-
pecia, gastrointestinal toxicity, peripheral neurotoxicity,
and impairment of fertility. These side-effects are experi-
enced by almost all of the patients with varying degrees
of severity, and usually, these events can be managed
successfully. However occasionally, more serious and
even life threatening complications may ensue mainly
involving vascular and pulmonary events. Deep venous
thrombosis (DVT) is encountered in about 8% of GCT
patients receiving cisplatin-based chemotherapy for
metastatic disease [4]. Pulmonary embolism secondary
to DVT may occur in up to 6% of cases [5,6]. Arterial
complications e. g. peripheral arterial thrombotic occlu-
sion, myocardial infarctions, and cerebral vascular events
are reported in about 0.3% of GCT patients receiving
chemotherapy [7]. Pulmonary fibrosis represents the
most important complication involving the lungs. This
complication is also called bleomycin induced pneumon-
itis (BIP) because it is clearly associated with bleomycin
if given in cumulative dosages of more than 300 mg
[8,9]. About 7% of chemotherapy cases will experience
BIP with 1% being fatal [10].
Multiple complications occurring synchronously or
metachronously in one patient have been reported [4,7].
But rarely, more than three serious complications will be
encountered in one individual [11]. Here we report a
case who experienced as many as four serious complica-
tions secondary to cisplatin-combination chemotherapy,
three vascular events and one pulmonary.Case presentation
This 48 years old patient with uneventful history pre-
sented with a left sided testicular seminoma. Beta Hu-
man chorionic gonadotropin (bHCG) was elevated to
247 U/l (normal range to 2 U/l) while Alpha fetoprotein
and Lactate dehydrogenase were within normal limits.
Computed tomography of chest and abdomen revealed a
retroperitoneal mass of 6 cm in size (Figure 1) and
another one of 2 cm size in the mediastinum corre-
sponding to clinical stage III (Lugano Classification) andto the good prognosis group according to IGCCCG clas-
sification [12].
The patient underwent inguinal orchiectomy and
according to the patient´s wish, a centralvenous port
system with access to the right subclavian vein was im-
planted at the same time. Low-dose anticoagulation
treatment was instituted thereafter with low molecular
weight heparin (Enoxiparin 40 mg daily). Three cycles of
the cisplatin/etoposide/ bleomycin chemotherapy regi-
men (PEB) were administered without delay between the
cycles. Acute side effects involved recurrent singultus
during all cycles, complete alopecia after the third cycle.
Routine laboratory examinations done weekly during
chemotherapy revealed transient increase of gamma glu-
tarate dehydrogenase, as well anemia with hemoglobin
of 8.9 g/dl. Serum creatinine increased during the appli-
cation of the third cycle of treatment to 1.5 mg/dl indi-
cating a considerable impairment of renal function. Also
during the third cycle, the patient reported of increasing
dyspnea upon slight exercise. In addition, at the end of
the third cycle, the patient experienced a sudden episode
of left upper abdominal pain. Routine restaging with
computed tomography of chest and abdomen after com-
pletion of the second cycle of chemotherapy revealed
partial remission of the lymphadenopathy but no other
significant findings. Final restaging after the third cycle
documented complete remission of the mediastinal mass
and subtotal remission of the retroperitoneal mass.
Figure 3 Computed tomography of chest and abdomen, coronary
section, performed after third cycle of chemotherapy, showing the
central venous port device with thrombosis (arrow) and subtotal
splenic infarction (arrow).
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Thus, cure had been achieved, oncologically. However,
chest CT also revealed fibrotic changes bilaterally in the
caudal parts of the lungs consistent with the typical find-
ings in Bleomycin induced pneumonitis (Figure 2).
Accordingly, pulmonary function testing revealed a
decrease of vital capacity to 44%. Also, the chest CT re-
vealed thrombosis of the centralvenous port system with
extension of thrombotic material into the subclavian
vein (Figure 3). In addition, the abdominal CT revealed
splenic infarction involving approximately one third of
the organ (Figure 3). Therapeutically, anticoagulation
therapy was increased to 80 mg Enoxaparin daily and
the venous port system was removed surgically. In
addition, corticosteroid therapy with 50 mg Prednisolone
p/o was applied for treatment of BIP resulting in some
improvement of dyspnea, subsequently. Three months
after completion of chemotherapy and despite ongoing
full dose heparin-based anticoagulation therapy, the
patient experienced a sudden loss of speech and amnesic
aphasia. Magnetic resonance imaging of the brain
disclosed infarction of the right-sided thalamic region
(Figure 4) as well as several additional small older is-
chemic regions in the temporal and occipital cortex,
respectively.
After all these complications genetic testing for inher-
ited thrombophilia documented heterozygote mutation
of factor V Leiden (FVL).
The patient was placed on life-long warfarin anticoa-
gulation therapy. 18 months after completion of chemo-
therapy, follow-up examinations revealed ongoing
complete remission, oncologically. The neurological
symptoms had resolved totally. The corticosteroid ther-
apy had been terminated 14 months after onset of BIP.
Exertional dyspnea has improved meanwhile, however,
vital capacity is still no more than 50%.Figure 2 Chest Computed tomography performed after third
cycle of chemotherapy showing diffuse interstitial infiltrates,
bilaterally, consistent with Bleomycin induced pneumonitis.Conclusion
Generally, the occurrence of complications secondary to
a chemotherapeutic agent is dependent on both the ap-
plied dosage of the drug and the predisposition of the
individual patient to acquire particular complications.
Accordingly, high dose chemotherapy is associated with
a much higher frequency of major complications. With
respect to the susceptibility of the patient to acquire
complications, older age is clearly one general predispos-
ing factor as well as pre-existing chronic diseases e.g.
Diabetes mellitus, renal insufficiency, chronic vascular
disease. As most of the patients with testicular GCT are
young and otherwise healthy, and as most of the metas-
tasized cases only require standard dose chemotherapy,
major complications are rather infrequent. Two or more
critical events arising simultaneously or consecutively in
one such patient are even more infrequent. Thus, the
conjunction of four serious events as experienced by our
patient is truly exceptional. O´Reilly reported a 26 year
old patient with testicular seminoma and no significant
comorbidity who sequentially experienced cerebral
stroke, deep vein thrombosis and pulmonary embolism
during PVB chemotherapy [11]. A 33 year old Dutch pa-
tient with GCT who was otherwise healthy developed
cerebral stroke and myocardial infarction upon cisplatin-
based therapy [13]. Likewise, in a German series, two
Figure 4 Axial Magnetic resonance Imaging (MRI) of the Brain
with Fluid Attenuated Inversion Recovery (FLAIR sequence), three
months after completion of chemotherapy: Hyperintense lesion
in the right thalamic region (arrow) indicating thalamic infarction.
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infarction and cerebral stroke were reported. Also in that
report, five cases with multivessel myocardial infarction
as well as two cases with pulmonary embolism occurring
in conjunction with cerebral stroke and with peripheral
arterial thrombosis, respectively, were documented [7].
With respect to the present patient, it is probably the
unique combination of a number of particular condi-
tions that instigated this extraordinary pattern of unto-
ward events.
Undoubtedly, the thrombophilic predisposition of this
patient documented by the mutation of Factor V Leiden
(FVL) represents the paramount pathogenetic factor that
triggered the major vascular complications. Heterozy-
gote status of FVL mutation is prevalent in around 5%
of the Caucasian population involving a seven-fold in-
crease of the thrombogenic risk in afflicted subjects [14].
Evidently, FVL does also modestly increase the risk of
arterial thrombosis [15-17], at least in the presence of
additional prothrombotic conditions [18]. Even splenic
infarction, one of the events of our patient, has been
documented in a case with FVL mutation [19].
Thus, our patient was bearing a genetically determined
significantly increased risk of thrombosis which was
superimposed by at least four additional synergistic
thrombogenic factors: age, cancer, central venous portsystem, and cisplatin chemotherapy. (I) Firstly, the
slightly advanced age of 48 years confers a minor in-
crease of general thrombotic risk by comparison to the
average GCT patient. (II) Cancer itself generally in-
creases the risk of thrombosis [20,21]. Moreover, there is
also clear evidence of further increased thrombotic risk
in those individuals who have both, cancer and FVL mu-
tation [14]. On top of that, our patient had a huge retro-
peritoneal mass that potentially might compromise
venous backflow from the lower limbs thus predisposing
to intravasal clotting [4]. (III) Central venous port de-
vices generally involve a high potential of thrombosis
due to contact and irritation of vascular walls with the
synthetic port material [22]. In the presence of FVL mu-
tation, an additional 3 – 6 fold thrombotic risk has been
documented [23,24]. (IV) Cisplatin combination chemo-
therapy involves considerable thrombogenic risk [25]
possibly caused by endothelial damage [6,26,27].
Whether or not anti-emetic steroid therapy and BIP-
related corticoid administration may have advanced the
thrombotic risk in our patient is at least conceivable
[28]. In all, our patient experienced three thrombotic
events during or immediately after cisplatin-based
chemotherapy. Obviously these complications were initi-
ated and promoted by the conjunction of the patient´s
genetically determined increased risk of thrombosis on
the one side, and several disease-related as well as treat-
ment related synergistic prothrombotic factors on the
other side.
With regard to the Bleomycin-related pulmonary fi-
brosis the patient used to be a non-smoker and he had
no apparent predisposing pulmonary conditions. Yet,
two minor precipitating factors could be noted, i.e. the
slightly advanced age of 48 years and the impaired renal
function developing during the third cycle of chemother-
apy, both of these conditions are known to be associated
with the occurrence of BIP [8]. At least on the experi-
mental level there is some evidence that FVL mutation
may promote pulmonary fibrosis, too [29]. Thus con-
ceivably, the pulmonary and the vascular complications
occurring in the present patient may share predisposing
factors.
From a clinical point of view, it must be asked how
and if at all these events could have been prevented.
Probably, the pulmonary complication represents much
of a chance event that had not been predictable at the
time of treatment. Two of the three vascular complica-
tions were endo-arterial events. So, low dose heparin
anticoagulation would probably not have been sufficient
to prevent further vascular events. If acetylic salicylic
acid (ASA) would have been beneficial in this case re-
mains elusive. However, what should be learned from
this extraordinary case is that genetic testing for heredi-
tary clotting disorders should be considered in all those
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cation. Then, life-threatening further complications
could be prevented by full dose warfarin medication or
other modern oral anticoagulation treatment.
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